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A B S T R A C T
Background: Implantable cardioverter-defibrillators (ICDs) are usually indicated for patients with 
malignant arrhythmias considered as high risk. Sympathetic hyperactivity plays a critical role in the 
development, maintenance, and worsening of ventricular arrhythmias. New treatment options in this 
population represent a clinical necessity. This study’s objective was to report the outcomes of patients 
with ICDs and electrical storm submitted to renal sympathetic denervation for arrhythmia control. 
Methods: Eight patients with ICDs admitted for electrical storm refractory to optimal medical 
therapy underwent renal sympathetic denervation. Underlying diseases included Chagas disease 
(n = 6), non-ischemic dilated cardiomyopathy (n = 1), and ischemic cardiomyopathy (n = 1). 
Information on the number of episodes of ventricular tachycardia/ventricular f ibrillation and 
antitachycardia therapies in the week before the procedure and 30 days after treatment were 
obtained through interrogation  of the ICDs.  
Results: The median numbers of episodes of ventricular tachycardia/ventricular f ibrillation, 
antitachycardia pacing, and shocks in the week before renal sympathetic denervation were 29 (9 to 
106), 23 (2 to 94), and 7.5 (1 to 88), and significantly reduced to 0 (0 to 12), 0 (0 to 30), and 0 (0 to 1), 
respectively, 1 month after the procedure (p = 0.002; p = 0.01; p = 0.003, respectively). No patients died 
during follow-up. There were no major complications related to the procedure. 
Conclusions: In patients with ICDs and electrical storm refractory to optimal medical treatment, renal 
sympathetic denervation significantly reduced arrhythmia load and, consequently, antitachycardia 
pacing and shocks. Randomized clinical trials in the context of renal sympathetic denervation to 
control refractory cardiac arrhythmias are needed to further support these findings.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. 
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 
 
Denervação simpática renal em pacientes com cardiodesfibrilador implantável e 
tempestade elétrica
R E S U M O
Introdução: Cardiodesfibriladores implantáveis (CDIs) são geralmente indicados para pacientes com 
arritmias malignas considerados de alto risco. A hiperatividade simpática desempenha um papel 
crítico no desenvolvimento, na manutenção e no agravamento de arritmias ventriculares. Novas opções 
de tratamento nessa população representam uma necessidade clínica. Nosso objetivo foi relatar os 
resultados de pacientes com CDIs e tempestade elétrica submetidos à denervação simpática renal para 
controle da arritmia. 
Métodos: Oito pacientes com CDIs internados por tempestade elétrica refratária ao tratamento médico 
otimizado foram submetidos à denervação simpática renal. Condições subjacentes foram: doença 
de Chagas (n = 6), cardiomiopatia dilatada não isquêmica (n = 1) e cardiomiopatia isquêmica (n = 1). As 
informações sobre o número de taquicardias ventriculares/fibrilações ventriculares e episódios de terapias 
antitaquicardia na última semana pré-procedimento e nos 30 dias pós-tratamento foram obtidas por meio 
de interrogação dos CDIs.
Resultados: As medianas dos episódios de taquicardias ventriculares/fibrilações ventriculares, sobre-
estimulação e choques na semana que antecedeu a denervação simpática renal foram de 29 (9 a 106), 23 (2 a 
94) e 7,5 (1 a 88), sendo significativamente reduzidas para 0 (0 a 12), 0 (0 a 30) e 0 (0 a 1), respectivamente, 1 mês 
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após o procedimento (p = 0,002; p = 0,01; p = 0,003). Nenhum paciente morreu durante o acompanhamento. 
Não ocorreram complicações maiores relacionadas ao procedimento.
Conclusões: Em pacientes com CDIs e tempestade elétrica refratária ao tratamento médico otimizado, 
a denervação simpática renal reduziu significativamente a carga de arritmia e, consequentemente, as 
sobre-estimulações e os choques. Ensaios clínicos randomizados, no contexto de denervação simpática 
renal para controle de arritmias cardíacas refratárias, são necessários para trazer maior robustez aos 
nossos achados. 
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Publicado por Elsevier Editora Ltda. 
Este é um artigo Open Access sob a licença de CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Implantable cardioverter-defibrillators (ICDs) have shown to 
be effective in primary and secondary prevention of sudden car-
diac death and are usually indicated for patients with malignant 
arrhythmias considered as high risk.1 Electrical storm is defined 
as the occurrence of three or more episodes of potentially malig-
nant ventricular arrhythmias (VAs) within a 24-hour period, 
whose reversion requires intervention with antitachycardia the-
rapy, i.e., antitachycardia pacing (ATP) or shock. This is a severe 
and dramatic event when repeated shocks are required, a fact 
that leads to hospital admission at the intensive care unit, causing 
considerable discomfort to patients in addition to premature ICD 
battery wear. The therapeutic options for patients with recurrent 
ICD shocks include drug treatment with antiarrhythmics and be-
ta-blockers,2-4 and catheter ablation.5,6 However, both approaches 
are associated with low efficacy in the long term, and in case of 
ablation, it may be associated with potential complications.7 New 
treatment options in this population of high-risk patients repre-
sent a medical necessity. 
Sympathetic hyperactivity plays a critical role in the develop-
ment, maintenance, and worsening of VAs.8 Percutaneous renal 
sympathetic denervation (RSD) has shown to reduce sympathetic 
activity9 and, therefore, decrease blood pressure in patients with 
resistant hypertension for up to 3 years of follow-up in some stu-
dies.10-12 The effects of RSD on the sympathetic nervous system 
activity suggest that this technique can be used in other diseases 
associated with increased sympathetic tone, such as chronic re-
nal disease, heart failure, and cardiac arrhythmias.13 Particularly 
for the treatment of cardiac arrhythmias, RSD has a strong phy-
siopathological rationale.14 Recently, some case reports have sug-
gested RSD benefits in patients with electrical storm.15,16 However, 
data are scarce and any conclusive analysis regarding this context 
is compromised. 
This study aimed to describe the results up to 30 days after RSD 




This was a prospective study conducted at Instituto Dante Paz-
zanese de Cardiologia, a single tertiary hospital in São Paulo, Brazil. 
The study was approved by the local Ethics Committee and perfor-
med according to good standards of clinical practice. All patients 
read, understood, and signed the Informed Consent, which contai-
ned the most important information on the research protocol pre-
sented in an instructive summary.
Thirteen consecutive patients admitted with VA refractory to 
optimal medical therapy and considered unsuitable for cardiac 
ablation were eligible for the study, between August 2013 and June 
2014. Diagnostic confirmation of electrical storm was attained 
through device interrogation, by means of the analysis of the sto-
red intracardiac electrograms and confirmation that the antitachy-
cardia therapies were appropriate and effective (Fig. 1). Electrical 
storm was defined as the occurrence of three or more episodes of 
sustained ventricular tachycardia (VT)/ventricular fibrillation (VF) 
within a 24-hour period, whose reversion required ATP or shock. 
Duration longer than 30 seconds and/or hemodynamic instability 
defined sustained ventricular tachycardia. Optimal medical treat-
ment comprised the control of possible triggering causes of VA, 
such as electrolyte disturbances and the use of antiarrhythmic 
drugs. Cardiac ablation was qualified as inadequate in the presence 
of polymorphic VT, VF, unstable arrhythmias, non-mappable ar-
rhythmias, intracardiac thrombus, or failure of previous ablation. 
Exclusion criteria included the following: active infection, signi-
ficant hypotension (systolic blood pressure ≤ 90 mmHg or need for 
vasopressor agents), renal failure (glomerular filtration rate - GFR 
< 45 mL/min) and renal arteries anatomically inadequate for inter-
vention (< 20 mm long or < 3.5 mm in diameter, presence of > 50% 
stenosis/fibrodysplasia/previous stent), or a solitary kidney. 
The ICD monitoring zone was programmed between 120 and 
130 bpm in all patients. Information on the number of VT/VF episo-
des and antitachycardia therapies (ATP and shocks) in the week be-
fore the procedure and 30 days post-treatment were obtained 
through ICD interrogation.
Renal sympathetic denervation procedure
RSD was performed as previously described.17 After obtaining 
femoral artery access, unfractionated heparin was administered 
at a dose of 100 IU/kg. Aortography along the renal arteries was 
performed with a pigtail catheter, followed by catheterization 
and selective renal arteriography using a Judkins catheter, after 
nitroglycerin administration (50 to 200 mcg). In all cases, the 
procedure was conducted using an irrigated tip radiofrequency 
ablation catheter (Therapy Cool PathTM; St. Jude MedicalTM – 
Minneapolis, USA). At least four radiofrequency (RF) lesions 
were made along both renal arteries, from the distal segment 
toward the ostia. The catheter was retracted 5 mm and turned 
after each radiofrequency application, thus producing a helical 
pattern of ablation. Due to the visceral pain caused using the 
ablation, analgesia was provided using fentanyl and morphine. 
At the end of the procedure, renal arteriography was performed 
to evaluate vascular integrity. 
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Post-procedure evaluation and clinical follow-up
The sheaths were removed when the activated clotting time rea-
ched values < 200 seconds. Manual hemostatic compression was 
performed for at least 20 minutes, followed by pressure dressing. 
Walking was allowed after 4 hours of rest, in the absence of bleeding 
at the puncture site. During the resting period, special attention was 
paid to the occurrence of vascular complications at the femoral ac-
cess, such as bleeding, hematomas, and pseudoaneurysms, as well as 
arrhythmia monitoring. Antiarrhythmic medications were maintai-
ned during follow-up. Patients were discharged after control of VA 
episodes. 
Statistical analysis 
Categorical variables are shown as absolute and relative frequen-
cies. Continuous variables are shown as mean ± standard deviation 
or median (range), and were compared using Student’s t-test or the 
Mann-Whitney test. Statistical analyses were performed using the 
IBM SPSS StatisticsTM program, version 22.0 (IBM – Armonk, USA). 




Of the 13 patients admitted with refractory VA, electrical 
storm was confirmed in 11, as one had accelerated idioventricular 
rhythm below the ICD detection zone, which persisted for several 
days, and another had frequent VAs, but did not meet the criteria 
for electrical storm diagnosis. Three patients were excluded from 
the study due to renal failure/active infection, single kidney, and 
absence of ICD (which prevented the accurate qualification/quan-
tification of VAs). 
In the eight remaining patients with electrical storm refractory 
to optimal medical therapy, cardiac ablation was considered inade-
quate in four due to polymorphic VT (three with previous unsuc-
cessful ablation), in three due to intracardiac thrombi, and in one 
Figure 1. (A) Diagnostic confirmation of electrical storm, through implantable cardioverter-defibrillator interrogation and analysis of stored intracardiac electrograms, confirming 
that the antitachycardia therapies were appropriate and effective. (B) The unsuccessful attempt at ventricular tachycardia reversion by antitachycardia pacing (ATP), triggering 
the onset of another ventricular tachycardia with different morphology, which was reversed by shock. VT: sustained ventricular tachycardia.
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with previous unsuccessful ablation/intracardiac thrombus. Table 
1 summarizes the baseline characteristics of each of the eight pa-
tients (four males, aged 63.6 ± 3.9 years) with ICD and electrical 
storm who were submitted to RSD and included in the analysis. 
Four were hypertensive; one was diabetic; four had dyslipidemia; 
one was a smoker; two had previous myocardial infarction; five 
had a previous stroke. Chagas disease was the most prevalent car-
diomyopathy etiology (n = 6), followed by one case of non-ischemic 
dilated cardiomyopathy and one case of ischemic cardiomyopathy. 
Mean ejection fraction was 0.28 ± 0.04. The ICDs had been implan-
ted for 5 ± 5.4 years (range 1 to 17 years). The number of antiarrhy-
thmic drugs ranged from 2 to 4 (3 ± 0.53). Three patients had signs 
of skin hyperpigmentation due to amiodarone use. 
Angiographic and procedure characteristics
Mean diameters of the left and right renal arteries were 5.11 ± 
1.01 mm and 5.13 ± 0.96 mm, respectively. The mean length of the 
right and left renal arteries were 41.0 ± 6.9 mm and 29 ± 9.8 mm, 
respectively. One patient had a polar artery on the right side, and 
two other cases had three polar arteries, being two on the right side 
and one on the left. Two patients had mild proximal stenosis in the 
renal artery. 
All procedures were performed by transfemoral approach. On ave-
rage, 88.1 ± 32.7 mL of contrast medium were used during 21.6 ± 16.0 
minutes of fluoroscopy. The mean number of radiofrequency applica-
tions was 6.3 ± 1.3 in the right and 4.9 ± 1.2 in the left renal artery. The 
angiographic and procedure characteristics are shown in Table 2. 
Procedural safety
The procedure was conducted without complications in all pa-
tients. Focal and slight reductions in the renal artery lumen with no 
limitations in blood flow were observed in two cases (distally in the 
left renal artery and distally in both renal arteries) immediately after 
radiofrequency application, which were attributed to spasms and/or 
edema. There were no complications related to the femoral puncture 
during the periprocedural period. There was no increase in serum 
creatinine levels (1.1 ± 0.3 mg/dL initial vs. 1.1 ± 0.2 mg/ dL after 
30 days; p = 0.73), indicating maintenance of GFR during follow-up.
Table 1
Baseline characteristics of each patient with implantable cardioverter-defibrillator (ICD) and electrical storm, submitted to renal sympathetic denervation.
Patient Age (years) Gender Cardiomyopathy 
etiology







1 70 M Chagas disease 0.30 17 Yes No A, BB, ACEI
2 62 M Non-ischemic 
dilated 
cardiomyopathy
0.34 3 No Yes A, BB, ACEI, L
3 62 M Ischemic 
cardiomyopathy
0.22 1 No Yes A, BB, ACEI
4 69 F Chagas disease 0.29 5 No No A, BB, ACEI
5 60 F Chagas disease 0.30 5 No Yes A, BB
6 64 F Chagas disease 0.22 1 No No A, BB, ACEI
7 62 M Chagas disease 0.30 1 Yes No A, BB, ACEI
8 60 F Chagas disease 0.28 7 Yes Yes A, BB, ACEI
M: male; A: amiodarone; BB: betablocker; ACEI: angiotensin-converting enzyme inhibitor; L: lidocaine; F: female.
Table 2
Angiographic and procedure characteristics.
Variable n = 8
RRA/LRA diameter, mm 5.11 ± 1.01/5.13 ± 0.96
RRA/LRA length, mm 41.0 ± 6.9/29 ± 9.8
Contrast volume, mL 88.1 ± 32.7
Time of fluoroscopy, minutes 21.6 ± 16.0
Number of radiofrequency applications on RRA/LRA 6.25 ± 1.28/4.86 ± 1.21
RRA: right renal artery; LRA: left renal artery.
Blood pressure levels remained stable up to 30 days (systolic 
blood pressure of 109.6 ± 20.7 mmHg initial vs. 107.3 ± 17.3 mmHg 
after 30 days; p = 0.81) and thus, adjustment in the chronic use of 
drugs due to ventricular dysfunction, present in all patients, was 
not required.
Effect of renal sympathetic denervation on ventricular arrhythmias 
and antitachycardia therapies
The median number of episodes of VT/VF, ATP, and shocks in the week 
before the RSD was 29 (9 to 106), 23 (2 to 94), and 7.5 (1 to 88), respecti-
vely, which was significantly reduced to 0 (0 to 12), 0 (0 to 30), and 0 (0 to 
1) 1 month after the procedure (p = 0.002; p = 0.01; p = 0.003, respecti-
vely). Only three patients had VA after the RSD: the first had one VT epi-
sode in the first week, which required a shock; the second had ten VT 
episodes in the first week, with spontaneous reversion and a VT in the 
fourth week, which required three ATPs and one shock; the third had 
two VTs and ten ATPs in the first week, one VT/11 ATPs and one shock in 
the second week, and nine VTs/nine ATPs in the fourth week. 
The total incidence of episodes of VT/VF and antitachycardia pacing 
(ATP and shocks) pre- and post-RSD is shown in Fig. 2. Figs. 3 to 5 show 
the median of episodes of VT/VF, ATP, and shocks, as well as the indivi-
dual response of each of the eight patients submitted to RSD. There 
were no changes in anti-arrhythmic drug schemes from hospital dis-
charge to the end of follow-up. No patients died during follow-up. 
Discussion
In patients with ICD and electrical storm refractory to optimal 
medical treatment, it was demonstrated that RSD significantly redu-
ces the arrhythmic load without procedure-related complications. 
In spite of the small number of subjects included in the study, this 
has been the largest series in this context.
It is noteworthy that this study included patients with Chagas di-
sease, non-ischemic dilated cardiomyopathy, and ischemic car-
diomyopathy, although most had Chagas disease etiology. It is 
possible that, in addition to the effect on the autonomic tone, RSD 
may result in beneficial side effects by reducing the excess volume 
and hormonal activation observed in treated patients with heart 
failure; however, despite significant cardiac dysfunction in all pa-
tients, none showed significant signs/symptoms of pulmonary con-
gestion/edema, which suggests that arrhythmia reduction was 
probably not related to heart failure improvement.   
The heart is densely innervated by sympathetic fibers and it is 
well established that their activation increases heart rate and facili-
tates atrioventricular conduction.18 In ventricles, the increase in 
sympathetic tone reduces the ventricular effective refractory pe-
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Figure 2. Overall incidence of episodes of ventricular tachycardia/ventricular fibrillation 
(VT/VF), antitachycardia pacing (ATP), and shock, pre- and post-renal sympathetic de-
nervation (RSD).
Figure 3. On the left, median of episodes of ventricular tachycardia/ventricular fibrillation (VT/VF) pre- and post-renal sympathetic denervation (RSD). On the right, individual 
response of each of the eight patients submitted to the procedure. 
Figura 4. On the left, median of antitachycardia pacing (ATP) episodes pre- and post-renal sympathetic denervation (RSD). On the right, individual response of each of the eight 
patients submitted to the procedure. 
riod, increases automaticity, and reduces the threshold for VA.19 In-
creasing clinical and preclinical evidence indicates that sympathetic 
modulation by surgical or catheter ablation may represent a new 
treatment option for cardiac arrhythmias.20 Vaseghi et al.21 recently 
demonstrated that surgical sympathetic denervation reduced ICD 
shock loads up to 90%; despite the promising results, the non-selec-
tive effects of surgical denervation may result in autonomic dys-
function, as demonstrated in this study with a small number of 
patients (change of 10% in the sweating pattern, 12% in skin sensiti-
vity, and persistent ptosis in one patient). 
Ukena et al.15 reported the first experiment in humans using per-
cutaneous RSD in two patients with heart failure and electrical 
storm: one patient with hypertrophic cardiomyopathy, monomor-
phic VT despite the use of multiple antiarrhythmic drugs, and prior 
unsuccessful endocardial/epicardial cardiac ablation; another pa-
tient with dilated cardiomyopathy, and frequent episodes of VF and 
polymorphic VT, who refused cardiac ablation. In both cases, a signi-
ficant reduction in VA was documented.  
Our group16 described a significant reduction in VF/VT episo-
des and appropriate ICD therapies in one patient with dilated car-
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diomyopathy and contraindication for cardiac ablation due to the 
presence of thrombus in the left ventricle, submitted to RSD with 
irrigated-tip catheter. Remo et al.22 have recently shown the be-
nefits of RSD as adjunctive therapy in refractory VT in four pa-
tients with underlying cardiomyopathy, with similar results in 
ischemic and non-ischemic patients. In an experimental model, 
Linz et al.23 were able to demonstrate that RSD by radiofrequency 
significantly reduced the occurrence of spontaneous VAs and at-
tenuated the increase in left ventricular end-diastolic pressure 
during ischemic events.
Intriguingly, six of the eight patients in this study had Chagas 
disease. Despite the implementation of socioeconomic measures 
and the development of drugs that allow treatment in the acute 
phase of the disease, chronic Chagas cardiomyopathy remains a 
major public health problem in many Latin American countries, af-
fecting approximately 15 to 16 million individuals, with a mortali-
ty rate of 20,000/year.24
Approximately two-thirds of individuals with chronic symptoms 
develop cardiac lesions, including severe ventricular dysfunction 
and dilation, tachyarrhythmias, bradyarrhythmias, and, not rarely, 
sudden death.25 Sudden death accounts for approximately 55-65% of 
overall mortality in patients with Chagas disease, which is higher 
than deaths from heart failure.26 The arrhythmogenic nature of Cha-
gas disease is related to the presence of fibrotic tissue interspersed 
with areas of preserved infarction and dyskinetic regions, genera-
ting an area of high propensity to complex VAs.27
VA treatment includes antiarrhythmic drugs, correction of rever-
sible causes, such as electrolyte disturbances, and cardiac abla-
tion.28-30 Although amiodarone reduces the risk of sudden death (by 
29%) and cardiovascular death (by 18%) in this population, antiar-
rhythmic therapy is neutral considering all-cause mortality and is 
associated with a two- and five-fold increase in the risk of lung and 
thyroid toxicity, respectively.31
Almost 50% of patients undergoing conventional endocardial 
ablation have arrhythmia recurrence.31 VT in chagasic patients fre-
quently has multiple sites of origin, including the subepicardium, 
and is hemodynamically unstable/non-mappable, which greatly 
hinders its approach.32 Epicardial ablation in these cases is often a 
challenge, especially in individuals with severe ventricular dys-
function and clinical deterioration. Therefore, RSD may represent 
an alternative treatment for patients with Chagas disease with re-
fractory VA. 
Figure 5. On the left, median shock episodes pre- and post-renal sympathetic denervation (DSR). On the right, individual response of each of the eight patients undergoing the 
procedure. 
There were no deaths in 30 days of follow-up. However, the 
follow-up period is short for drawing conclusions regarding mortali-
ty in this high-risk population included in the study, with advanced 
heart disease and severe ventricular dysfunction, which are poor 
prognostic predictors.
Study limitations
The non-randomized design, the relatively small sample size, and 
the absence of a control group represent potential study limitations, 
although there is no other publication more significant on the sub-
ject. Although sympathetic activity was not directly measured, the 
significant association between RSD and VA load reduction was re-
markable. Most patients had Chagas cardiomyopathy, and the res-
ponse to RSD might be distinct in this population.
Conclusions
This study showed the importance of sympathetic hyperactivity 
in patients with ventricular arrhythmia, and suggested the potential 
performance of catheter-based renal sympathetic denervation in 
this scenario. In patients with implantable cardioverter-defibrillator 
and electrical storm refractory to optimal medical treatment, renal 
sympathetic denervation significantly reduced the arrhythmia load 
and, consequently, antitachycardia pacing and shocks. Randomized 
controlled trials strictly designed in the context of renal sympathe-
tic denervation to control refractory cardiac arrhythmias are needed 
to further support these findings. If proven to be safe and effective in 
this context, sympathetic denervation will become an important 
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